Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group)

重组人鼠嵌合抗CD20单克隆抗体（丽珠集团）

Report date: 2023/05/05 17:34:33

Base Information

Drug NameRecombinant anti-CD20 chimeric monoclonal antibody (Livzon Group)

Drug Alias Name利妥昔单抗生物仿制药（丽珠集团）利妥昔单抗生物类似药（丽珠集团）LZM-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesLivzon Pharmaceutical Group Inc

China Registration ClassN/A

Develop Information

Active CompaniesLivzon Pharmaceutical Group Inc Livzon Mabpharm Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02